National Bank of Canada
BCTX

National Bank of Canada’s Briacell Therapeutics BCTX Stock Holding History

National Bank of Canada’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.64K Buy
+802
New +$3.73K ﹤0.01% 2579
2025
Q3 		– Sell
-65
Closed -$1.43K – 2868
2025
Q2 		$1.43K Sell
65
-29
-31% -$1.06K ﹤0.01% 2649
2025
Q1 		$2.86K Buy
94
+43
+84% +$2.05K ﹤0.01% 2462
2024
Q4 		$4.36K Sell
51
-1
-2% -$120 ﹤0.01% 2466
2024
Q3 		$9.66K Buy
52
+2
+4% +$225 ﹤0.01% 2090
2024
Q2 		$8.03K Hold
50
– – ﹤0.01% 2174
2024
Q1 		$16.7K Hold
50
– – ﹤0.01% 2063
2023
Q4 		$40K Buy
50
+33
+194% +$23.7K ﹤0.01% 1837
2023
Q3 		$14.9K Hold
17
– – ﹤0.01% 2103
2023
Q2 		$15.9K Hold
17
– – ﹤0.01% 2068
2023
Q1 		$18.4K Hold
17
– – ﹤0.01% 1992
2022
Q4 		$10.8K Buy
+17
New +$14.4K ﹤0.01% 2161
2022
Q3 		– Sell
-119
Closed -$103K – 2697
2022
Q2 		$103K Sell
119
-927
-89% -$916K ﹤0.01% 1554
2022
Q1 		$1.59M Buy
1,046
+847
+426% +$1M ﹤0.01% 949
2021
Q4 		$248K Buy
+199
New +$261K ﹤0.01% 1407

Other funds holding BCTX

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
LCM
LuminArx Capital Management New York $136M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

National Bank of Canada's BCTX Position: Q1 2026 in Review

National Bank of Canada opened a new position in Briacell Therapeutics (BCTX) in Q1 2026: 802 shares worth $2.64K. The stake represents ﹤0.01% of the portfolio and ranks #2579 among its holdings. This is a return to the name: National Bank of Canada previously reported a position in BCTX as recently as Q2 2025.

National Bank of Canada first reported a position in BCTX in Q4 2021 and has held it in 15 quarters since. The position peaked at $1.59M in Q1 2022. 16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

  • National Bank of Canada held 802 shares of Briacell Therapeutics worth $2.64K as of Q1 2026.
  • Briacell Therapeutics was a new National Bank of Canada position in Q1 2026.
  • Briacell Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2579 holding.
  • National Bank of Canada first reported a position in Briacell Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • National Bank of Canada's Briacell Therapeutics position peaked at $1.59M in Q1 2022.
  • 16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.